Chronic obstructive pulmonary disease (COPD)

Clinical Pharmacist’s monthly news round-up: the top 10 in October 2014

What has been happening in the world of pharmacy? Here’s our pick of must-read news from the past month……

Combination inhaler Anoro Ellipta launched for COPD

Anoro Ellipta, a novel inhaler containing a long-acting muscarinic receptor antagonist and a selective long-acting beta-2 adrenergic receptor agonist, may find a limited place in therapy.…

Paradoxical bronchoconstriction occurs in 5% of COPD patients treated with beta-2-agonists

African–American patients with COPD are more likely to be affected by therapy-induced bronchoconstriction, study suggests.…

Potential role for benralizumab in COPD patients with eosinophilia

Benralizumab therapy led to a numerical, albeit not statistically significant, improvement in COPD exacerbations and lung function compared with placebo.…

Simvastatin has no therapeutic benefit in COPD, researchers conclude

Simvastatin does not prevent exacerbations in people with moderate-to-severe chronic obstructive pulmonary disease (COPD)…

Cognitive impairment linked to COPD

Patients with chronic obstructive pulmonary disease (COPD) may be at increased risk of mild cognitive impairment (MIC), a study has suggested (Mayo Clinic Proceedings 2013;88:1222).…

Knowing the differences between COPD and asthma is vital to good practice

This content was published in 2011. We do not recommend that you take any clinical decisions based on this information without first ensuring you have checked the latest guidance. The “Outcomes strategy for people with chronic obstructive pulmonary disease and asthma” was launched in July 20…

COPD: clinical features and diagnosis

Chronic obstructive pulmonary disease is an incurable condition affecting millions of people worldwide.…

COPD: management

For patients with chronic obstructive pulmonary disease, inhaled medicines are the mainstay of treatment.…